Aled achieved his MChem in Chemistry with Medicinal Chemistry from Imperial College London in 2010. After a year working at an analytical development CRO, he then began his PhD on the chemical synthesis of peptide-oligonucleotide conjugates for RNA silencing applications at the University of Manchester. Aled completed his PhD in 2015, and then moved into industry as an analytical development scientist at Bristol Myers Squibb. Here, he was involved in several late-stage development projects, supporting analytical control strategy development and long-term stability studies. He moved to the Chemical Development function of AstraZeneca in 2017, where he enhanced his project leadership skills by leading the analytical development of several early and late-stage clinical projects, authoring regulatory submission modules, leading analytical tech transfer to CMOs worldwide, as well as being involved in the design and roll-out of a new chromatography data system. Aled joined CatSci in 2020 as a Senior Scientist, before his promotion to Group Leader. Aled is dedicated to delivering excellent quality, perfect-for-purpose analytical solutions that address the needs of our customers so that they can get medicines into the hands of patients efficiently and effectively.